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Objectives: To identify possible existence of therapeutic misconception and its effects 
on clinical trials in sub-Saharan Africa.
Data source: Original research findings and reviews published in the English literature 
and author’s professional experience with clinical trials in some East, Central and 
West African countries.    
Design: Review of peer-reviewed articles.
Data extraction: Online searches and requests for reprints from corresponding authors 
and institutional subscription.
Data Synthesis:  Information categorised accordingly.
Results: Therapeutic misconception, defined as a conflation by research subjects of 
research goals and those of routine health care is considered widely prevalent globally. 
The subjects misunderstand the disclosures during consenting process and enroll hoping 
to derive personal benefits from the study. Though no study has looked at therapeutic 
misconception specifically in sub-Saharan Africa, available evidence suggests that it 
is prevalent. Therapeutic misconception is incompatible with informed voluntary 
consent. It may affect participation in clinical trials, subjects’ safety and well-being 
and possibly the research findings.
Conclusions: There is need for studies to identify the prevalence and effects of 
therapeutic misconception in the region. Researchers in sub-Saharan Africa should 
be aware of its existence, thus design trials in which it will not have significant effects 
and strengthen the consent process to reduce it. 
INTRODUCTION
Clinical research is essential for development of new 
knowledge related to health promotion, prevention 
and clinical treatment of health conditions and the 
understanding of various health problems. Over the 
past 15 to 20 years there has been an upsurge in the 
number, scope and size of clinical trials which has been 
accompanied by globalisation thereof (1). The spatial 
geographical distribution of disease conditions to be 
studied, the need to test the safety and efficacy of new 
therapies in diverse situations and populations due 
to potential effects of social, ecological and genetic 
disparities have influenced internationalisation of 
clinical research (2-4). Other factors include the need 
to reduce trial costs by increasing subject recruitment 
rates and shortening trial periods.
 International ethics on new therapies or devices 
require that before they can be routinely used in 
clinical situations or for prevention of diseases they 
must be rigorously tested in human beings with or at 
risk of acquiring the respective health condition under 
well controlled situations. Randomised clinical trials 
(RCTs) are considered “the gold standard” in clinical 
research as they provide the most reliable data for 
evidence-based clinical/health care. Randomisation 
of the subjects among the various treatment arms of 
the study reduces the effects of factors other than the 
intervention/therapy being tested thus promoting 
confidence in the results thereof. In these trials the 
investigational drug, vaccine, device or therapeutic 
approach/preventive strategy is compared to either 
a standard one or a placebo (5).
 For preventive trials such as vaccine or HIV 
prevention strategies such as male circumcision, 
healthy volunteers who are individuals at risk of 
acquiring the respective conditions are invited to 
participate in the trials through local media outlets, 
messages from health care providers or health 
facility notice boards. In cases of therapeutic trials 
such as those on ARVT, antimalarials, antibiotics, 
cancer chemotherapy, or surgical techniques various 
categories of patients with the respective health 
condition are likewise invited to participate, by 
their attending physicians or researchers. In either 
case the potential subjects must give informed 
consent voluntarily before they can be enrolled into 
the trials (4-7). This must be achieved through an 
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interactive, continuous process between a designated 
member of the research team and the patient/subject 
before, during and even beyond the trial period 
depending on the trial (7).  The goal is to ensure that 
the trial participants achieve informed decisions and 
implement them appropriately. Faden and Beauchamp 
gave three stages of the consent process; 
(i) Transmission and reception of relevant 
information
(ii) Comprehension of  the  transmitted 
information
(iii) Use of the information to arrive at a 
decision.
The disclosure should include among other issues:
(i) The nature and purpose of the study.
(ii) The procedures involved including 
randomisation, use of placebos and why; the 
laboratory tests, follow up (home) visits - how 
long and why?
(iii) Any foreseeable risks and benefits in 
participating.
(iv) Appropriate and available alternatives to 
participation including non-treatment in some 
cases.
(v) That participation is voluntary and one may 
withdraw at any stage of the study without 
prejudice.
(vi) Explanation on the differences between research 
(clinical trial) and routine clinical/health care, 
especially the fact that one may not receive an 
effective therapy and the loss of personalised 
care inherent in clinical care (6, 7, 9, 10).
The information must be disclosed in a manner and 
language that will facilitate understanding by the 
potential subjects. The subject must be competent 
to make decision based on their comprehension of 
the information and voluntarily decision to either 
participate in the trial or not.
 There have been concerns though whether 
and how much of the disclosures research subjects 
understand and retain or whether they really 
appreciate the implications of their decision to 
participate (11- 13). Either as a result of the nature of 
disclosures or subjects’ comprehension thereof or both, 
some patients/subjects may not quite understand the 
differences between research and routine health/
clinical care and therefore the implications of their 
enrollment. The Belmont Report (6) defines research 
by its purpose that is “an activity designed to test 
an hypothesis, permit conclusions to be drawn and 
thereby contribute to generalisable knowledge”. 
When research subjects conflate between the goals 
of research/clinical trials and those of clinical/health 
care they are said to have “therapeutic misconception” 
(9, 14-17).
This article is a review of evidence on the prevalence 
and effects of therapeutic misconception in the English 
literature. It also explores the possible existence of 
the phenomenon and its potential effects on clinical 
trials in sub-Saharan Africa, as well as makes 
recommendations on strategies to address the gap 
in information from the region and reduce it.
The therapeutic misconception
Definition: Therapeutic misconception was first 
described by Appelbaum et al (14) as the “mistaken 
belief by research subjects that research like therapy 
they have received before, is designed and will be 
executed in a manner of direct benefit to them”. Lidz 
et al (16) refined it thus “therapeutic misconception 
occurs when a research subject fails to appreciate 
the distinction between the imperatives of clinical 
research and of ordinary (routine) treatment and 
therefore inaccurately attributes therapeutic intent 
to research procedures”. 
 The National Bioethics Advisory Commission 
(NBAC) defined therapeutic misconception as 
“the belief that the purpose of a clinical trial is 
to benefit the individual patient, rather than to 
gather data for the purpose of contributing to 
scientific knowledge (18). Macklin (19) characterised 
therapeutic misconception as ‘the belief that research 
is promising treatment intended to benefit study 
participants”.  Lately Henderson et al (20) offered 
a new definition that “therapeutic misconception 
exists when individuals do not understand that the 
defining purpose of clinical research is to produce 
generalisable knowledge, regardless of whether the 
subjects enrolled in the trial may potentially benefit 
from the intervention under study or from other 
aspects of the clinical trial.
 There are some disagreements though as to 
the definition of therapeutic misconception (20, 
21). While acknowledging that some consider over 
estimation of clinical benefits from an experimental 
intervention as well as under estimation of 
potential risks of harm to be part of therapeutic 
misconception. Horng and Grady (21) describe 
different scenarios of misunderstanding by research 
subjects. They drew distinctions among “therapeutic 
misconception”,”therapeutic mis-estimation” and 
“therapeutic optimism”. They noted that therapeutic 
misconception (TM) has been used rather loosely 
to refer to any number of misunderstandings that 
subjects may have in the research context, but 
agree with others (14, 17, 22, 23) that therapeutic 
misconception is a conflation by research subjects 
of research goals with those of clinical care. They 
however define “therapeutic mis-estimation” as “a 
misunderstanding of the probability of benefits and/
or harm in research”, while “therapeutic optimism” 
is “hope for the best outcome”. They contend that 
misunderstanding the nature and intent of research is 
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most ethically problematic, while mis-estimating the 
probability of direct benefits may be less worrisome 
(21).
 Simon et al (24) described a similar scenario in 
preventive clinical trials noting the similarities and 
differences between them and therapeutic trials. They 
referred to it as “preventive misconception” (PM) and 
defined it as “the over estimation of probability or 
level of personal protection that is afforded by being 
enrolled in a trial of a preventive intervention”.
Origins: Clinical trials share certain characteristics 
with routine medical/health care which may blur the 
boundary between research and therapy or preventive 
health care services to not only the patients/subjects 
but also the health care providers/investigators.
 Most clinical trials are often carried out within 
local health facilities or established research facilities. 
The same health facilities are used by the local 
community from which the patients/subjects  will 
be drawn for routine health care including health 
education and preventive services. The research 
investigators are drawn from amongst the health 
care providers in the same facilities. Clinical trials 
use drugs or treatment devices, the same as in 
routine health care. The procedures used in clinical 
trials such as history taking, physical examination, 
laboratory tests are also used in routine medical 
care. The subjects for phase III therapeutic clinical 
trials are patients with the same health condition 
under study and who will have come to the same 
facilities seeking medical attention for their ailments. 
For preventive clinical trials the subjects are healthy 
individuals at risk of acquiring the health condition 
under study. Both groups may be just too eager 
to get a cure for their condition or prevention of a 
dreaded and life-threatening condition. In either 
case the subjects expect that physicians/health care 
providers will only invite them to participate in a 
clinical trial when such participation would be in 
their best interest while others may enroll with the 
belief that the drugs/intervention offered in clinical 
trials are of a superior quality (15, 25).
 Clinical trials are a fairly new phenomenon in 
sub- Sahara Africa (SSA). Many people especially in 
rural areas may not have had previous experience with 
clinical trials/research, whereas most may have sought 
medical care either for themselves or their relations in 
the same facilities. Health facilities such as hospitals, 
health centres are generally known for treatment 
and/ or preventive care, rather than for clinical trials/
research. Health care providers including doctors, 
nurses, laboratory technologists are by their training 
expected to provide the best care available to their 
patients and patients trust their professionalism. 
Prevalence: Studies conducted in the more developed 
countries have shown that therapeutic misconception 
is widely prevalent in clinical trials (9, 19, 25, 26). Lidz 
et al (9) stated that therapeutic misconception is a 
widely recognised problem in informed consent, but 
did not specify the prevalence thereof.  In their later 
study Lidz et al (16) in which they interviewed 225 
subjects enrolled in 44 clinical protocols 62% of them 
were judged to manifest therapeutic misconception. 
Appelbaum et al (15) reported that 69% of patients 
in their survey were unaware of the fact that their 
assignment to treatment interventions would be 
randomised and 40% expected their assignment 
would be made on the basis of their therapeutic 
needs.
 Personal benefits have been reported to be the 
major motive behind research participation even in 
studies with little or no prospect of benefit (25, 26). 
Riecken and Ravich (13) reported that 75% of their 
subjects’ reason for participating in a clinical trial 
was desire for personal benefit. Penman et al (27) 
interviewed 144 cancer patients in a number of phase 
II and III clinical trials, and observed that although 
the consent documents clearly indicated that benefits 
could not be assured, 43% of the subjects stated that 
they had no doubts at all about personal benefits from 
the study interventions. Schaeffer et al (26) reported 
that 100% of subjects in phase I studies described their 
studies as having both research and treatment aims. 
Ellis et al (28) observed that 74% of subjects in their 
survey thought the doctor would ensure that they 
receive the best treatment available in a randomised 
clinical trial.
 Although there has been no study specifically 
looking at or which has identified prevalence of 
therapeutic misconception in (SSA), there is  lot of 
evidence indicating poor understanding of research 
goals and/or informed consent disclosures. Joubert et 
al (29) in their study on consent for a vitamin A trial in 
South Africa observed that there was generally poor 
knowledge about the trial and 92.3% of the subjects 
felt they had to stay in the study to get good medical 
care. In a PMTCT project in Cote d’Ivoire, Ekouevi et al 
(30) found that only 48% of the participants reported 
to have understood the information disclosed. Krosin 
et al (31) in their study on consent process in Mali 
noted that 93% of the subjects did not understand 
they were enrolled in an investigation as opposed to 
receiving therapy, implying that they hoped to receive 
treatment for their conditions by participating in the 
trial. More recently Oduro et al (32) in Ghana, reported 
that 70% of the study participants gave personal 
direct benefits as their reason for participating in the 
clinical trial and only 20% recalled being told about 
study-related risks. 
Factors influencing therapeutic misconception: It is 
agreed that therapeutic misconception exists when 
a research subject fails to appreciate the distinction 
between the imperatives of research and those of 
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routine clinical/health care and therefore inaccurately 
attributes therapeutic intent to research procedures. 
However subjects may understand the goals and 
methods of research project but still claim therapeutic 
motivation for participating, while others may fail to 
understand the aims of a particular research project 
or the procedures therein, yet they do not attribute 
therapeutic intent for their enrollment. Certain factors 
have been shown to influence the occurrence of 
therapeutic misconception among patients/subjects 
participating in clinical trials.
The title of the protocols as well as terms used to describe 
the trial: Sometimes brand names or acronyms are 
used in the title of the protocol such as ALIVE, 
PROVED, MAGIC. These may suggest the outcome 
of the trial before it starts. Terms like “therapeutic 
trial” “treatment trial” “HIV prevention trials”, or 
titles which do not clearly spell out what the trial 
entails may mislead the potential participants. Other 
terms commonly used in clinical trial protocols such 
as “randomisation” and “placebo” have been shown 
not to be well understood or interpreted by the lay 
population from which majority if not all of clinical 
trial subjects are drawn. Featherstone and Donovan 
(33) reported that subjects who had participated 
in a clinical trial interpreted “at random” to mean 
“without purpose”, while Waggoner et al (34) in their 
study involving a general public sample found that 
only 22% of them knew the meaning of the word 
“randomly”. In a study on decision-makers,  that is, 
parents and guardians for childhood leukaemia trials, 
Kodish et al (35) reported that 50% of them did not 
understand the concept of randomisation.
 
The consent documents: The language used in consent 
documents may be above the literacy level of most 
potential subjects. They may therefore not being 
comprehensible to them (36). Even when the documents 
are translated into local languages as required by ethics 
committees (ECs) they may still not be understood 
by majority of the potential subjects, or the meaning 
therein may be lost. At the same time some terms such 
as “random” “placebo” do not have equivalent in some 
languages. The contents of the consent documents are 
very critical in facilitating decision making process for 
the potential subjects (8, 13, 36). Some documents do not 
state the purpose of the study or what will be done, the 
benefits and/or risk of harm to participants. Horng and 
Grady (21) in a study of 272 consent forms for phase I 
therapy studies found that 99% of them explicitly stated 
that the purpose was experimental research and 92% 
indicated that the primary aim was to assess safety. On 
the other hand, Henderson et al (37) in a survey of 39 
informed consent documents for phase I gene transfer 
trials, observed that 74% did not clearly convey to the 
subjects that benefit was neither likely nor expected, 
but instead used the term “indeterminate”.
The way the messages therein are packaged and or 
disseminated may also be a contributory factor. It 
has been shown that many patients/subjects have 
deficiency in correctly interpreting risk and/or 
benefits expressed as percentages (37). When male 
circumcision for prevention of HIV infection was 
being rolled out in some countries in SSA for example, 
some individuals interpreted the 60% protection to 
mean that if they reduced their sexual partners by a 
factor of 40% they would be okay! Some consented 
with that belief in mind. There may at times be 
more emphasis or over-estimation of the benefits of 
participation, with exclusion or downplay of potential 
risks, adverse events of the intervention or procedures 
involved in the trial.
The subjects: In phase III therapeutic clinical trials, 
the subjects are patients with varying degrees of 
the clinical condition under study. Some may have 
had previous treatment for the same condition with 
varying success rates and perceptions thereto. Others 
may be seeking treatment for their conditions for 
the first time. The psychological reaction/response 
to the illness varies a lot among the patients and/or 
their close family relations or friends. For phase III 
preventive clinical trials the subjects are healthy 
volunteers at risk of acquiring the health condition 
under study. Their knowledge of the disease or a 
friend or relation who has suffered from it as well as 
their fears and perceived risk of acquiring the disease 
may influence their decision to volunteer. Some may 
enroll out of fear of the health condition, its nature 
and desperation. Many subjects cite the hope of 
benefit even when there is little hope thereof, as a 
prominent reason foe enrolling in clinical trials (32). 
Patients/subjects may enroll in a clinical trial with 
the belief that they will receive better treatment/care 
(12), that their assignment to a treatment arm or the 
intervention will be tailored to their best interests 
even when told explicitly that randomisation will 
be used (9, 25).
 Understanding of disclosure and reaction thereto 
varies a lot among individuals. Aaronson et al (38) 
observed that overall understanding of disclosures 
correlated with age and education, being better among 
the young and more educated. Lidz (23) reported 
that 62-86% of subjects manifested substantial error 
in appreciating the issues in participating in clinical 
trials. Others may not understand the scientific 
methodology (15). At times the patient/subject may 
misinterpret the disclosure.
 Having cognitive ability to make rational 
decision and receiving adequate information does 
not necessarily lead to an adequate understanding of 
issues at hand. Most individuals make context-bound 
rather than context-free decisions. Their illness and 
severity thereof may influence their decision-making 
process, as shown by Schaeffer et al (26). Patients/
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subjects’ trust (misplaced trust) in the health care 
providers/researchers and institutions involved 
either because of previous experience or standing in 
society may also influence therapeutic misconception. 
It has been shown that some categories of people may 
have low or high tendency to fall prey to therapeutic 
misconception. African-Americans are said to have 
low tendency as they are more suspicious of clinical 
researchers and have less favourable attitudes 
towards research (25, 39). This may also apply to 
some populations based on their experience with 
clinical trials or health care providers/institutions.
The investigators and institutions: The subjects are 
recruited from among the general population or 
patients by their health care providers or invited/
encouraged through institutional bulletins or adverts. 
The investigators themselves may confuse research 
and therapy in their informed consent process with 
potential subjects. Professional identify, that is, as 
physicians, may interfere with their decision to 
recruit their own patients into clinical trials due to a 
conflict between their allegiance to patient care and 
clinical research/trial. Patients may thus enroll in a 
study on invitation or suggestion by their physicians 
trusting that they will put their health care interest 
before anything else.
 What the researchers disclose to potential 
subjects is central to their decision-making. Some 
may deliberately be selective in what they disclose. A 
study by Verheggen et al (40) showed that investigators 
emphasised aspects of the trial they expected 
patients/subjects would understand easily and not 
those they would have difficulty in understanding 
such as study design, randomisation and selection 
procedures. Sometimes the researchers rarely plan 
meaningful discussion beyond the study purpose 
and procedures or what is contained in the standard 
consent documents. Efforts are not made to explain 
the nature of the research, differences between the 
goals thereof and those of routine clinical/health 
care as well as implications of their participation. 
Lidz (23)  state that researchers are often unwilling or 
even fail to acknowledge to themselves that the care 
they offer in a clinical trial is not optimised for the 
patient/subjects’ benefit which may blur the consent 
process. Henderson et al (37) stated that the ways 
in which the investigators describe the likelihood 
of benefits in a study have a strong influence on 
occurrence of therapeutic misconception in their 
study subjects. Some may use or explain probability 
of risk or benefits in percentages or proportions in a 
manner that distort the reality.
 At times researchers fail to disclose or discuss 
aspects of the research which limit subjects 
personalised care in clinical trials (13), or may use the 
consent process in a way that favours subjects accrual 
in clinical trials so as to realise the target numbers in 
the shortest possible time.
 The fact that clinical trials are conducted in 
established health facilities where subjects mix with 
other patients and the fact that these institutions may 
have a good reputation may contribute to misplaced 
trust that they will offer state of the art care.
Effects of therapeutic misconception: As stated above 
therapeutic misconception exists when a research 
subject inaccurately attributes therapeutic intent 
to research participation. The subjects confuse the 
goals of research with those of routine health care. 
Their enrollment into the study is therefore premised 
on the belief that they will derive personal benefits 
there from. Therapeutic misconception may therefore 
affect the informed consent given for enrollment as 
well as the subjects’ participation in the study, thus 
presenting an ethical problem in clinical trials (9).
Effect on informed consent: Truly informed voluntary 
consent implies that the research participants have 
understood the essence of the study, their rights 
and responsibilities as research participants. For 
it to achieve its goals of promoting autonomy and 
decision-making, it is critical that patients/subjects 
not only understand the elements of the disclosures 
but also appreciate its applicability to their individual 
situations or that of their children in case of parents 
or guardians consenting on behalf of minors. When 
people do not understand or accept scientific 
explanation of health and disease and by extension 
clinical trials obtaining informed consent can be a 
daunting challenge (18).
 While some subjects may clearly understand the 
disclosure during consenting process and give their 
consent voluntarily, they may still have therapeutic 
misconception if their goal for participating is personal 
benefit. Therapeutic/ preventive misconception 
represents lack of meaningful informed consent  and 
participants may not appreciate the consequences of 
their decisions (41). Subjects manifesting therapeutic 
misconception can therefore not be said to have 
given informed and voluntary consent for their 
participation. 
Effect on participation: It is agreed that truly informed 
and voluntary consent is a pre-condition for ethical 
involvement of human subjects in clinical trials (4, 6, 
16). Informed consent is among other things meant 
to ensure that only eligible individuals according 
to the nature and goals of the research protocol are 
recruited and enrollment into the respective study. 
Therapeutic misconception may therefore affect 
participation in a clinical trial in a number of ways. 
Subjects who may not be eligible as per protocol 
requirements may be inadvertently enrolled. It has 
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been suggested therapeutic misconception may lead 
to an increase in recruitment (25). However no study 
has specifically evaluated it.
 Subjects may be exposed to harmful effects of 
the study procedures or the intervention and/or 
sustain adverse effects which they may neither relate 
to their participation in the trial nor report back to 
the research team as required. Desperate patients/
subjects may be induced to accept unreasonable risks 
on the false assumption that their situation “can not 
get any worse”, thus casting a shadow over demands 
for beneficence and respect (17).
 When the expected benefits either a cure or 
prevention of the health condition is not realised, 
the participants/subjects may lose trust in the health 
facility/ research institution as well as their health 
care providers/researchers. They may feel let down 
by their health care providers. This may not only 
affect future research/clinical trials but also their 
health seeking behaviours (25, 39). When the subjects 
discover that they are not on the interventions they 
had hoped to be put on, they may on top of losing 
trust in the team, drop out from the study, thus 
potentially affecting the study results (39). 
 For preventive trials subjects who have 
preventive misconception may exhibit behavioural 
changes which may put themselves as well as other 
people at greater risk of acquiring the disease (24, 
41, 42). This is particularly worrying with regards 
to HIV prevention trials interventions.
DISCUSSION
   
Internationalisation of clinical trials, while a relatively 
new phenomenon is bound to increase in number, 
scope and size for among other reasons economic 
concerns related thereto (1), emergence of new disease 
conditions and need to test efficacy and safety of new 
drugs, therapeutic devices and preventive strategies 
in diverse populations and conditions (2, 3). Some 
disease conditions such as HIV/AIDS, tuberculosis, 
malaria, childhood diarrhoeal diseases, while global 
they are more prevalent and with more serious 
sequelae in developing countries, SSA included. 
Hence the need to conduct relevant clinical trials in 
the region.
 Despite international guidelines which govern 
research involving human beings, there have and 
continue to be considerable controversies around 
ethics of clinical trials originated, sponsored or 
conducted by industrialised countries and carried out 
in developing countries (43, 44). The controversies 
have been brought to the fore by clinical trials on HIV 
in developing countries. It is however not limited 
thereto.
 Although therapeutic misconception is widely 
prevalent among research subjects globally (9, 16, 
26, 27), there have been no studies specifically on 
this phenomenon in SSA. However several studies 
conducted in the region over the past ten or so years, 
have documented poor understanding of various 
aspects of research protocols including the consent 
disclosures. Ekouevi et al (30) reported that only 48% 
of subjects understood the information disclosed. 
Krosin et al (31) in Mali found that 93% of subjects 
thought they were receiving routine therapy, implying 
that they did not understand what they were told 
during the consent process regarding the nature of 
the trial. Moodley et al (45) reported that only 21% 
participants of their study in South Africa could recall 
being randomly allocated to treatment arms of the 
study and 19% of those on a placebo-controlled study 
knew what placebo meant. Only 10% of participants 
in a vaccine trial in the Gambia understood that a 
placebo would be used (46), while Oduro et al (32) 
observed that only 20% of the subjects in a trial in 
Ghana recalled being told about study-related risks 
during consent process. 
 Therapeutic misconception exists when research 
subjects conflate the imperatives of research with those 
of routine health care, thus attributing therapeutic 
intent to research procedures (9, 15-17). The question is 
which and to what extent does the misunderstanding 
observed amongst study participants in SSA constitute 
therapeutic misconception< If the phenomenon is 
widely prevalent in the developed countries, with 
their higher literacy levels, better health systems and 
facilities, it may not be far-fetched to believe that it 
is equally or even more prevalent in SSA. Krosin et 
al (31) averred that the degree of miscomprehension 
observed in their study in Mali was more than that 
found in similar studies in developed countries.
 This may not be surprising as the factors known 
to influence occurrence of therapeutic misconception, 
such as titles and terms used to describe the research 
protocols, the language used and contents of consent 
documents, the nature and severity of the health 
condition under study and subjects desperation for 
cure/prevention, or their trust in their health care 
providers/investigators and/or health/research 
institutions, may be of particular concern in SSA, 
with its unique situations such as poverty, poor/weak 
health systems and socio-cultural factors. Karim et al 
(12) in their study in South Africa found that 22% of 
the participants enrolled with the hope of receiving 
better medical care. Molyneux et al (47) described 
the role of trust by parents in misunderstanding of 
studies for which they consented for their children to 
participate in Kenya. Life-threatening conditions such 
as HIV/AIDS, malaria, cancer, which are prevalent 
in SSA against a background of non-availability of 
better alternative or any treatment options and the 
conditions under which clinical trials are carried out 
compared to those pertaining to routine health care 
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may influence potential subjects’ decision-making to 
enroll in clinical trials thus contributing to therapeutic 
misconception (48).
Of greater concern with regards to therapeutic 
misconception in SSA is its potential effect on informed 
consent and subjects’ participation in clinical trials 
and the quality of research findings. Joubert et al (29) 
concluded that with the poor knowledge amongst 
participants in their study in South Africa, they could 
not have been considered to be informed. Patients/
subjects will consent to participate in trials with the 
hope and belief that they will derive personal benefits 
there from. They may therefore be exposed to research-
related risks which they may neither appreciate nor 
report. In SSA with a myriad of disease spectrum, 
some with overlapping symptoms and varied cultural 
beliefs on causality of diseases and tendency to seek 
traditional medicine for treatment, this could pose a 
serious problem. An individual believing that he/she 
or his/her children have been protected against a 
particular disease, may wrongly assign symptoms 
of the disease to other conditions or blame them on 
witchcraft, evil spirits, etc and may not seek medical 
help. When they discover that they are not receiving 
the intervention they expected to get on enrolling, 
they may become bitter and angry, lose their trust 
in the investigators and institutions and may drop 
out from the study. If the proportion of those who 
drop out or those with serious adverse events do not 
report back to the research team is significant it could 
have an impact on the research findings. Others may 
not participate in future clinical trials or may change 
their health seeking behaviour henceforth because 
they feel let down by the people they trusted. For 
preventive clinical trials the perceived notion of 
protection, for example, against HIV infection, may 
lead to behavioural changes. The subjects may adopt 
risky behaviours as shown by Bartholow et al (21) and 
Chesney et al (42). These observations are of major 
concern as we scale up HIV prevention trials and 
strategies in SSA.       
CONCLUSIONS AND RECOMMENDATIONS
The prevalence and effects of therapeutic/preventive 
misconception in SSA remains largely unknown 
despite the overwhelming evidence thereof from 
developed countries. This may be due to the fact 
that clinical trials are a fairly new phenomenon in 
the region, or lack of awareness of the phenomenon 
by researchers in the region.
 Based on available evidence on the extent of 
misunderstanding of research related issues in 
SSA, some of which may contribute to therapeutic 
misconception, it is not far-fetched to infer that it is 
equally if not more prevalent and that the effects 
thereof may have serious impact on subjects’ informed 
consent, research participation and quality of research 
findings. 
 Sadly despite overwhelming evidence on 
the prevalence of therapeutic misconception and 
numerous calls to design and implement strategies 
to either eliminate or reduce it, therapeutic 
misconception continues to be tolerated and even 
fostered in some cases.
 Therapeutic misconception is incompatible 
with adequate informed consent and undermines 
the trustworthiness of clinical trials and research in 
general.
Cognisant of the foregoing, it is recommended 
that:-
(i) There is need for research studies in different 
settings and communities in SSA to identify 
the prevalence, determinants and effects of 
therapeutic misconception.
(ii) Researchers should design clinical trials in 
such a manner that therapeutic misconception 
will have limited consequences that is, avoid 
as much as possible the use of placebos in 
randomised clinical trials.
(iii) Researchers should ensure that they provide 
adequate disclosures during consenting 
process in particular explain the differences 
between research and routine clinical/health 
care and loss of personalised care in clinical 
trials.
(iv) Researchers should ensure the consenting 
process is continuous throughout the study 
period and not a one-off event before 
enrollment.
(v) There is need to create public awareness on 
the differences between research and routine 
health care, risks and benefits of participating 
in clinical trials, the subjects rights and 
responsibilities.
(vi) There is need to develop and build capacity 
of local Ethics Committees and Institutional 
Review Boards so that they may adequately 
review research protocols and consent 
documents, thus protecting subjects’ rights, 
safety and well-being.
(vii) There is need to create awareness amongst 
researchers in SSA on the existence of therapeutic 
misconception, its impact on clinical trials and 
possible strategies to reduce it.
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